• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Beckman Coulter awarded expanded contract for sepsis algorithm

Beckman Coulter awarded expanded contract for sepsis algorithm

May 18, 2020 By Sean Whooley

Beckman Coulter announced that it received an expanded partnership with BARDA for its expanding COVID-19 medical countermeasure portfolio.

BARDA (the Biomedical Advanced Research and Development Authority, part of the U.S. Dept. of Health and Human Services) awarded Beckman Coulter the partnership in collaboration with Dascena, Inc. The collaboration will offer advanced research and development toward optimizing a machine-learning-based sepsis diagnostic and prediction algorithm to include use with COVID-19 patients.

The algorithm builds on Beckman Coulter’s existing Early Sepsis Indicator that the FDA cleared last year. It combines the monocyte distribution width novel laboratory test parameter values with Dascena’s electronic health record data-based machine learning algorithm to predict and detect sepsis.

Beckman Coulter chief medical officer Dr. Shamiram Feinglass said in a news release that COVID-19 is changing the cause of sepsis cases, forcing a paradigm shift in the way the industry thinks about sepsis, leading to the collaboration to produce a prediction algorithm that helps detect sepsis regardless of whether it is bacterial or viral-induced.

“The global impact that COVID-19 has had on the health system is undeniable,” Beckman Coulter hematology business senior VP & GM Peter Soltani said in the release. “It has changed the way the industry thinks about so many things, and sepsis is no exception.

“Beckman Coulter is deeply committed to the fight against COVID-19 and has been working diligently to quickly bring quality SARS-CoV-2 serology assays to the market. We are thrilled to expand our partnership with BARDA, so we can extend that commitment to our sepsis research and begin clinical trials that include COVID-19 patients.”

Filed Under: Big Data, Business/Financial News, Contract Manufacturing, Diagnostics, Digital Health, Electronic Medical Records (EMR), Genomics/Molecular Diagnostics, Health Technology, Software / IT Tagged With: Beckman Coulter Inc., coronavirus, COVID-19, Dascena, Dept. of Health & Human Services (HHS), U.S. Biomedical Advanced Research and Development Authority (BARDA)

More recent news

  • Neuralink files to raise $649M in new equity offering
  • BofA: Surgical robot remanufacturing not a major setback for Intuitive
  • InspireMD wins CE Mark approval for CGuard Prime
  • Philips reports first cases for VeriSight Pro 3D ICE catheter in Europe
  • Ceryx Medical raises $15M to support bioelectronic pacemaker

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy